Insulet Q3 2021 Earnings Report
Key Takeaways
Insulet Corporation reported a strong third quarter with revenue reaching $275.6 million, an increase of 17.8% compared to the prior year. The company saw growth across its Omnipod product line, particularly in the U.S., and achieved record new customer starts. Insulet is on track for Omnipod 5 clearance later this year.
Third quarter revenue reached $275.6 million, up 17.8% year-over-year.
Total Omnipod revenue increased by 22.7% to $260.3 million.
U.S. Omnipod revenue grew by 26.4% to $167.2 million.
Operating income was $33.7 million, representing 12.2% of revenue.
Insulet
Insulet
Insulet Revenue by Segment
Forward Guidance
The Company expects revenue growth of 19% to 25% for the quarter ending December 31, 2021. Revenue growth ranges by product line are: Total Omnipod of 17% to 22%, U.S. Omnipod of 22% to 27%, International Omnipod of 7% to 13%, and Drug Delivery of 45% to 65%.
Positive Outlook
- Total Omnipod revenue growth of 17% to 22%
- U.S. Omnipod revenue growth of 22% to 27%
- International Omnipod revenue growth of 7% to 13%
- Drug Delivery revenue growth of 45% to 65%
Revenue & Expenses
Visualization of income flow from segment revenue to net income